Oladapo Bakare to Drug Design
This is a "connection" page, showing publications Oladapo Bakare has written about Drug Design.
Connection Strength
0.728
-
Akinboye ES, Rosen MD, Denmeade SR, Kwabi-Addo B, Bakare O. Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer. J Med Chem. 2012 Sep 13; 55(17):7450-9.
Score: 0.386
-
Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. Prostate. 2016 Jun; 76(8):703-14.
Score: 0.123
-
Akinboye ES, Bamji ZD, Kwabi-Addo B, Ejeh D, Copeland RL, Denmeade SR, Bakare O. Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. Bioorg Med Chem. 2015 Sep 01; 23(17):5839-45.
Score: 0.118
-
Bakare O, Ashendel CL, Peng H, Zalkow LH, Burgess EM. Synthesis and MEK1 inhibitory activities of imido-substituted 2-chloro-1,4-naphthoquinones. Bioorg Med Chem. 2003 Jul 17; 11(14):3165-70.
Score: 0.051
-
Ogindo CO, Khraiwesh MH, George M, Brandy Y, Brandy N, Gugssa A, Ashraf M, Abbas M, Southerland WM, Lee CM, Bakare O, Fang Y. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives. Bioorg Med Chem. 2016 08 15; 24(16):3849-55.
Score: 0.031
-
Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate. 2008 Oct 01; 68(14):1570-81.
Score: 0.018